Unknown

Dataset Information

0

The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice.


ABSTRACT: IFN-beta, a type I IFN, is widely used for the treatment of MS. However, the mechanisms behind its therapeutic efficacy are not well understood. Using a murine model of MS, EAE, we demonstrate that the Th17-mediated development of autoimmune disease is constrained by Toll-IL-1 receptor domain-containing adaptor inducing IFN-beta-dependent (TRIF-dependent) type I IFN production and its downstream signaling pathway. Mice with defects in TRIF or type I IFN receptor (IFNAR) developed more severe EAE. Notably, these mice exhibited marked CNS inflammation, as manifested by increased IL-17 production. In addition, IFNAR-dependent signaling events were essential for negatively regulating Th17 development. Finally, IFN-beta-mediated IL-27 production by innate immune cells was critical for the immunoregulatory role of IFN-beta in the CNS autoimmune disease. Together, our findings not only may provide a molecular mechanism for the clinical benefits of IFN-beta in MS but also demonstrate a regulatory role for type I IFN induction and its downstream signaling pathways in limiting Th17 development and autoimmune inflammation.

SUBMITTER: Guo B 

PROVIDER: S-EPMC2276397 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3578929 | biostudies-literature
| S-EPMC3504131 | biostudies-literature
| S-EPMC2118427 | biostudies-literature
| S-EPMC4529209 | biostudies-literature
| S-EPMC3855890 | biostudies-other
| S-EPMC7643080 | biostudies-literature
| S-EPMC2373838 | biostudies-literature
2008-12-01 | E-GEOD-12218 | biostudies-arrayexpress
| S-EPMC4123420 | biostudies-literature
| S-EPMC3746493 | biostudies-literature